The US FDA has granted its fast-track designation for SymBio Pharmaceuticals’ brincidofovir IV for the treatment of adenovirus infection in pediatric patients, the company said on April 26.The drug maker is currently conducting a multinational PII study, mainly in the…
To read the full story
Related Article
- SymBio Starts Nonclinical Study of Brincidofovir IV for Brain Tumors
September 9, 2021
BUSINESS
- Sanofi Files Dupixent for CSU in Children Aged 2-11 in Japan
December 26, 2025
- Enhertu Wins 5th China Indication in HER2-Low/Ultralow Breast Cancer
December 26, 2025
- SymBio Bags Rights to Develop Antiviral Brincidofovir for Alzheimer’s
December 26, 2025
- Dayvigo Wins Triple Crown in November HP Promotion List: Intage
December 26, 2025
- Pharma Hails End to “Spillover” Rule, Vows to Keep Fighting Off-Year Cuts
December 25, 2025
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…





